Charles River Laboratories
CRL
405 hedge funds and large institutions have $6.63B invested in Charles River Laboratories in 2019 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 139 increasing their positions, 153 reducing their positions, and 42 closing their positions.
7% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 42
1% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $14.3M
1% less funds holding
Funds holding: 409 → 405 (-4)
2% less capital invested
Capital invested by funds: $6.78B → $6.63B (-$150M)
9% less repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 153
1.09% less ownership
Funds ownership: 96.89% → 95.81% (-1.1%)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| 1 |
HM
HealthCor Management
New York
|
+$49.4M |
| 2 |
Bank of New York Mellon
New York
|
+$43.9M |
| 3 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$29.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$28.2M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$26.8M |
Top Sellers
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$42.2M |
| 2 |
Millennium Management
New York
|
-$34.7M |
| 3 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$32.6M |
| 4 |
Renaissance Technologies
New York
|
-$30M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$25.5M |
CRL Hedge Fund Activity: Q2 2019 in Review
405 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2019, worth a combined $6.63B — down 2.2% from $6.78B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CRL positions and 42 closed out — a net gain of 3 holders — while 139 added to existing stakes and 153 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $49.4M. The largest seller was Assenagon Asset Management, cutting an estimated $42.2M.
- 405 institutional investors held Charles River Laboratories (CRL) as of Q2 2019, down from 409 in Q1 2019.
- Funds reported $6.63B of Charles River Laboratories stock for Q2 2019, down 2.2% quarter-over-quarter.
- 45 funds opened new Charles River Laboratories positions in Q2 2019 and 42 closed out, a net change of +3 holders.
- The largest Charles River Laboratories buyer in Q2 2019 was HealthCor Management, an estimated $49.4M added.
- The largest Charles River Laboratories seller in Q2 2019 was Assenagon Asset Management, an estimated $42.2M sold.
Based on aggregated 13F filings for Q2 2019.